Hemogenyx Pharmplc Ls 01 Stock Revenue
5HU Stock | EUR 4.14 0.62 13.03% |
HEMOGENYX PHARMPLC LS 01 fundamentals help investors to digest information that contributes to HEMOGENYX PHARMPLC's financial success or failures. It also enables traders to predict the movement of HEMOGENYX Stock. The fundamental analysis module provides a way to measure HEMOGENYX PHARMPLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to HEMOGENYX PHARMPLC stock.
HEMOGENYX |
HEMOGENYX PHARMPLC LS 01 Company Revenue Analysis
HEMOGENYX PHARMPLC's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition |
Based on the latest financial disclosure, HEMOGENYX PHARMPLC LS 01 reported 0.0 of revenue. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The revenue for all Germany stocks is 100.0% higher than that of the company.
HEMOGENYX Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HEMOGENYX PHARMPLC's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HEMOGENYX PHARMPLC could also be used in its relative valuation, which is a method of valuing HEMOGENYX PHARMPLC by comparing valuation metrics of similar companies.HEMOGENYX PHARMPLC is currently under evaluation in revenue category among its peers.
HEMOGENYX Fundamentals
Return On Equity | -0.32 | |||
Return On Asset | -0.18 | |||
Shares Outstanding | 979.75 M | |||
Shares Owned By Insiders | 15.17 % | |||
EBITDA | (2.62 M) | |||
Net Income | (2.08 M) | |||
Cash And Equivalents | 1.81 M | |||
Total Debt | 1.63 M | |||
Debt To Equity | 1.86 % | |||
Current Ratio | 1.08 X | |||
Book Value Per Share | 0.01 X | |||
Cash Flow From Operations | (1.8 M) | |||
Earnings Per Share | (0.01) X | |||
Number Of Employees | 10 | |||
Beta | 3.34 | |||
Market Capitalization | 24.89 M | |||
Z Score | 9.0 |
About HEMOGENYX PHARMPLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HEMOGENYX PHARMPLC LS 01's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HEMOGENYX PHARMPLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HEMOGENYX PHARMPLC LS 01 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in HEMOGENYX Stock
HEMOGENYX PHARMPLC financial ratios help investors to determine whether HEMOGENYX Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HEMOGENYX with respect to the benefits of owning HEMOGENYX PHARMPLC security.